Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: BD, Cardiofocus, Flo Health, Hologic, Innova, Integrity Implants, New View Surgical, Penumbra.
Although the U.S. CDC considers myocarditis to be a rare event linked to mRNA COVID-19 vaccines, the FDA is adding a warning about the adverse event to its doctor and patient fact sheets for the vaccines.
It has been a bumpy rollercoaster ride for many biopharma companies throughout the pandemic, but overall, the 17 firms that make up BioWorld’s Infectious Disease Index are coming out ahead this year with stocks up by 44.8%.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aarkus, Aleta, Alzheon, Celsion, Cerecor, Chemomab, Cocrystal, Dermtech, Etherna, Kedrion, Liminal, Mercaptor, Microbiotica, Mynd, Public Health Vaccines, Qu, Recursion, Scancell, Sorrento, SQZ, Tessa, Titan, Tiziana, Xenter.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Corelink, Fist Assist Devices, Onkos Surgical, Phase Scientific.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aidoc, Aptar, Avania, Garwood, Icometrix, Imarc, Integrum, Mirador, Prognos, Sorrento Therapeutics, Thermo Fisher Scientific, Voluntis.
While biopharma deals are very much in line with the early pandemic months of 2020, mergers and acquisitions are telling a different story – one in which values are down by 76%. As of June 22, BioWorld has recorded 956 deals, including licensings, collaborations and joint ventures, valued at $80.2 billion in 2021, as well as 59 completed M&As worth $29.1 billion. In comparison with the same timeframe in 2020, the volume of both deals and M&As is down slightly by about 10 deals each, but the lack of high-value M&As, or mega-mergers worth more than $10 billion, has placed 2021 far behind last year. Deal values, however, are up by 4%.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anna, Augment, Big Cypress, Bioaxone, Cantex, Cybin, Fujitsu, Gyroscope, Iksuda, Legochem, Moderna, SAB, TFF, Vtv.
RSS
